{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:36:14Z","timestamp":1787877374736,"version":"build-2784847793"},"reference-count":23,"publisher":"Oceanside Publications Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Atopic dermatitis (AD) may develop by 6 months of age, and its severity assessment is essential for appropriate treatments. Scoring Atopic Dermatitis (SCORAD) is suggested to evaluate the severity of AD but is cumbersome for routine clinical use. The serum thymus\n and activation-regulated chemokine (TARC) is used as a marker of AD severity. However, the normal range of the TARC levels varies by age, and its usefulness for the evaluation of AD severity has not been established in patients ages &lt; 6 months. Here, we evaluated the correlation between\n serum TARC levels and SCORAD scores in early infancy and sought the optimal cutoff level to indicate AD severity.  <jats:bold>Methods:<\/jats:bold> The subjects were 35 patients with AD (16 girls and 19 boys; 3\u20105 months of age) who visited our clinic between April 2015 and March 2017. All\n the patients were physically examined by a board-certified allergist. The AD severity was determined by using the SCORAD, together with serum levels of TARC, total immunoglobulin E (IgE), lactate dehydrogenase, and peripheral eosinophil counts. Receiver operating characteristic curve analysis\n was performed to determine the cutoff levels of serum TARC to indicate AD severity.  <jats:bold>Results:<\/jats:bold> Significant correlations were observed between SCORAD scores and the serum TARC levels, peripheral eosinophil counts, and serum IgE levels (r = 0.640, r = 0.723, r = 0.533, respectively).\n The optimal cutoff levels of serum TARC to indicate mild and severe AD were &lt;3523 pg\/mL (area under the curve [AUC] = 0.856) and &gt;6192 pg\/mL (AUC = 0.833), respectively.  <jats:bold>Conclusion:<\/jats:bold> Although this study had limitations, we suggest that serum TARC is useful as a marker\n of AD severity in patients &lt;6 months of age.<\/jats:p>","DOI":"10.2500\/aap.2022.43.220034","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T04:31:22Z","timestamp":1662438682000},"page":"461-467","source":"Crossref","is-referenced-by-count":6,"title":["Serum thymus and activation-regulated chemokine (TARC) levels correlate with atopic dermatitis disease severity in patients &lt; 6 months"],"prefix":"10.2500","volume":"43","author":[{"given":"Munemitsu","family":"Koizumi","sequence":"first","affiliation":[{"name":"From the Department of Pediatrics, Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyo","family":"Kuzume","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Ishida","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terumi","family":"Midoro-Horiuti","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of Texas Medical Branch, Galveston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.alit.2020.02.006","article-title":"Japanese Guidelines for Atopic Dermatitis 2020","volume":"69","author":"Katoh","year":"2020","journal-title":"Allergol Int"},{"key":"B2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/all.13309","article-title":"Validation of patient-reported global severity of atopic dermatitis in adults","volume":"73","author":"Vakharia","year":"2018","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/ced.14948","article-title":"Longitudinal course and phenotype of health-related quality of life in adults with atopic dermatitis","volume":"47","author":"Schwartzman","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000247298","article-title":"Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis","volume":"186","year":"1993","journal-title":"Dermatology"},{"key":"B5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2133.2007.08112.x","article-title":"Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD, and the three-item severity score","volume":"157","author":"Oranje","year":"2007","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3388\/jspaci.28.119","article-title":"The differences in assessment of the disease activity of atopic dermatitis among physicians and numerical indexes based on blood tests","volume":"28","author":"Koizumi","year":"2014","journal-title":"Jpn J Pediatr Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group","volume":"10","author":"Hanifin","year":"2001","journal-title":"Exp Dermatol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis - a review on behalf of the International Eczema Council","volume":"147","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/ACI.0000000000000198","article-title":"Biomarkers for atopic dermatitis: a systematic review and meta-analysis","volume":"15","author":"Thijs","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2500\/aap.2020.41.200067","article-title":"Atopic dermatitis: correlation of severity with allergic sensitization and eosinophilia","volume":"41","author":"Ha","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"B11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1442-200X.2009.02908.x","article-title":"Changes in serum lactate dehydrogenase activity in children with atopic dermatitis","volume":"52","author":"Morishima","year":"2010","journal-title":"Pediatr Int"},{"key":"B12","first-page":"1712","article-title":"Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity","volume":"6","author":"Vekaria","year":"2017","journal-title":"F1000Res"},{"key":"B13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1067\/mai.2001.113237","article-title":"Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity","volume":"107","author":"Kakinuma","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3388\/jspaci.19.744","article-title":"Clinical utility of serum TARC\/CCL17 for monitoring clinical course of atopic dermatitis in children","volume":"19","author":"Fujisawa","year":"2005","journal-title":"Jpn J Pediatr Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jdermsci.2006.06.002","article-title":"Thymus and activation regulated chemokine (TARC\/CCL17) and skin diseases","volume":"43","author":"Saeki","year":"2006","journal-title":"J Dermatol Sci"},{"key":"B16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2222.2006.02430.x","article-title":"Increased serum thymus and activation-regulated chemokine and cutaneous T cell-attracting chemokine levels in children with atopic dermatitis","volume":"36","author":"Song","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"B17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1399-3038.2007.00692.x","article-title":"Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis","volume":"19","author":"Nakazato","year":"2008","journal-title":"Pediatr Allergy Immunol"},{"key":"B18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1399-3038.2009.00851.x","article-title":"Serum measurement of thymus and activation-regulated chemokine\/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age specific analysis in atopic dermatitis","volume":"20","author":"Fujisawa","year":"2009","journal-title":"Pediatr Allergy Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1399-3038.2011.01225.x","article-title":"Serum TARC and CTACK concentrations in children with atopic dermatitis, allergic asthma, and urticaria","volume":"23","author":"Machura","year":"2012","journal-title":"Pediatr Allergy Immunol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/1346-8138.12440","article-title":"Thymus and activation-regulated chemokine\/CCL17 as a clinical biomarker in atopic dermatitis","volume":"41","author":"Kataoka","year":"2014","journal-title":"J Dermatol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.15586\/aei.v49i3.191","article-title":"Infantile atopic dermatitis: serum vitamin D, zinc, and TARC levels and their relationship with disease phenotype and severity","volume":"49","author":"Esenboga","year":"2021","journal-title":"Allergol Immunopathol (Madr)"},{"key":"B22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/1346-8138.15294","article-title":"Influence of corticosteroid therapy on viral reactivation in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"47","author":"Tohyama","year":"2020","journal-title":"J Dermatol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0009-8981(02)00131-6","article-title":"Evaluation of human thymus and activation-regulated chemokine concentrations in blood using a new sandwich ELISA base on monoclonal antibodies","volume":"322","author":"Morita","year":"2002","journal-title":"Clin Chim Acta"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2022\/00000043\/00000005\/art00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:33:42Z","timestamp":1742358822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2022.43.220034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9,1]]}},"alternative-id":["1088-5412(20220901)43:5L.461;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2022.43.220034","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}